Directors and Company Secretary
LiDCO Group Plc Directors
Peter Grant – Non-Executive Chairman
Mr Grant joined the Board as Non Executive Director and Chairman Designate on 6 March 2017. On 10 May 2017, he was appointed Chairman of the Board. Mr Grant was Chief Executive Officer of Skyepharma PLC from January 2012 to June 2016, until its merger with Vectura Group plc. He joined Skyepharma as Chief Financial Officer in November 2006. Prior to Skyepharma, Mr Grant was Interim Chief Executive Officer of Voice Commerce Group, Group Finance Director at Eurodis Electron plc, Chief Financial Officer at WorldPay plc, Group Chief Executive at Molins plc and Finance Director at Molins plc. Prior to this he held a variety of senior commercial, financial and general management roles in the General Electric Company plc group of companies. He holds an MA in Mathematics from the University of Oxford and is a Chartered Accountant. Mr Grant is Chairman and Chair of the Finance and Audit Committee and member of the Remuneration Committee of Microsaic Systems plc and a Non-Executive Director of Labatec Pharma SA, a private Swiss company. Mr Grant is Chairman of the Audit and Nomination Committees and a member of the Remuneration Committee of the Company.
Matthew Sassone – Chief Executive Officer
Mr Sassone was appointed to the Board on 15 June 2015 and took over the role of Chief Executive Officer on the retirement of Dr Terry O’Brien on 14 August 2015. He has over 19 years’ experience in the medical industry having started his career in sales for Quintiles in 1996. He spent 12 years at Smiths Medical in various sales, marketing and business development roles achieving the role of Managing Director, Northern and Eastern Europe and Russia in 2010. In 2012 he moved to ArjoHuntleigh, a division of the Getinge Group, as Senior Vice President Global Marketing and was subsequently appointed Chief Marketing Officer of Maquet, also a division of Getinge. Mr Sassone has a degree in biochemistry with microbiology. Mr Sassone is a member of the Group’s Nomination Committee.
Tim Hall – Chief Financial Officer
Tim Hall joined the Board on 11 March 2019 as Chief Financial Officer and Company Secretary. Tim is a Chartered Accountant with almost 30 years’ experience in financial roles in the life science industry.
Prior to joining LiDCO, Tim was Chief Financial Officer of Oxford Gene Technology IP Ltd (“OGT”) from 2012 to 2018 during which time he helped to grow the business substantially through both geographic expansion and M&A activity before its successful sale to Sysmex Corporation in 2017. Before moving to OGT, Tim was Finance Director at AIM-listed Lombard Medical Technologies PLC for six years and previously had senior finance roles in UCB S.A, Celltech Group plc and Medeva PLC. Tim’s early career included finance and project management roles at Glaxo Wellcome plc/Wellcome plc. Tim qualified as a Chartered Accountant with Touche Ross & Co, now Deloitte.
Phil Cooper – Non-Executive Director
Mr Cooper was appointed in August 2016. He has 30 years of experience in the medical device industry and grown businesses through geographical expansion, introduction of new products and concepts and the creation of new customer channels and segments. Having gained experience in sales, sales management and logistics he was appointed UK Marketing Director for the Clinical Division of SCA Molnlycke and subsequently, on its sale to private equity in 1998, UK Managing Director of Molnlycke Health Care. In 2001 he joined the Group Executive Board and initiated the Customer Procedure Tray business for Molnlycke, now the European market leader. From 2005 he focussed on the Wound Care Division business and was appointed President in 2007. In his tenure as President from 2007 to 2014, Molnlycke became the global leader for advanced wound dressings and the market leader in the US and Europe, also entering directly in a number of key Asia-Pacific territories. Since 2014 Mr Cooper has been an independent advisor to a number of health care companies. He is a non-executive director and member of the Remuneration Committee of Alesi Surgical Limited and a Non-Executive Director of the Supervisory Board of Soest Medical Group. Mr Cooper is the Chair of the Remuneration Committee and a member of the Audit and Nomination Committees.
James Wetrich – Non-Executive Director
Mr Wetrich was appointed in August 2019. James brings with him over 35 years of experience in the US healthcare industry having worked both in the medical device and healthcare provider sectors, including companies such as Abbott Laboratories, Molnlycke Healthcare, Premier Inc, and Providence Health & Services. In the mid-1980s, James played an instrumental role in the formation of the University HealthSystem Consortium, now part of Vizient. This extensive work in the US healthcare supply chain has resulted in expert knowledge of the purchasing cycle including value analysis, strategic sourcing, supply chain relationship building and procurement logistics. Mr Wetrich is a member of the Remuneration and Nomination committees.
Tim Hall – Company Secretary